Compare Lionsgate Studios Corp Common Shares (LION) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lionsgate Studios Corp Common Shares vs Zimmer Biomet Holdings Inc — how do they compare? Lionsgate Studios Corp Common Shares trades at $10.86 (market cap $3.24B), while Zimmer Biomet Holdings Inc trades at $92.24 (market cap $17.50B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 5.4× Lionsgate Studios Corp Common Shares's market cap, and Zimmer Biomet Holdings Inc pays a 1.05% dividend while Lionsgate Studios Corp Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lionsgate Studios Corp Common Shares for 0 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| LION | ZBH | |
|---|---|---|
Market Cap | $3.24B | $17.50B |
Volume | 3,214,595 | 1,890,029 |
Sector | Technology | Health |
52-Week High | $16.40 | $103.98 |
52-Week Low | $5.91 | $79.58 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $6.75B | $24.57B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LION trades at $11.12, up 0.36% on the day, with a market cap of approximately $1.3 billion. The stock shows mixed signals: strong analyst support (87.5% buy rating) and a consensus price target of $16.80 suggest upside, but negative net income and shareholder equity highlight financial strain. Recent Q1 2027 earnings beat estimates with EPS of $0.37, yet the company remains unprofitable with a net loss of $128.5 million in 2025. Takeover interest from firms like Bolloré adds speculative appeal.
The outlook hinges on operational turnaround and potential M&A. Revenue growth from hit films like 'Michael' and a valuable content library offer catalysts, but high debt ($3.65B total) and consistent losses pose significant risks. Investors should weigh the 51% upside to price targets against fundamental weaknesses and industry volatility.
Zimmer Biomet (ZBH) trades at $92.08, down 0.1% on the day, with a bullish technical outlook supported by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 8.56%. A quarterly dividend of $0.24 was recently declared, payable in October 2026.
The investment outlook is cautiously optimistic, driven by earnings beats and analyst consensus pointing to upside. Key risks include rising debt levels and competitive pressures. The consensus price target of $103.11 suggests potential appreciation, but investors should weigh margin trends and macroeconomic factors affecting healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lionsgate Studios Corp Common Shares
Lionsgate Studios Corp. is a standalone content company that develops, finances, produces, and distributes motion pictures and television series, licensing its content to theaters, streaming platforms, television networks, and home entertainment channels.
Read more on LION →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
